Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals and Alligator Bioscience AB today announce that they have entered into a manufacturing services and supply agreement for the production of monoclonal antibody Drug Substance and Drug Product for pre-clinical studies and Phase I-II clinical trials.
Under the terms of the agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.
Peter Coleman, CEO of Cobra Biologics said: "Having been through a rigorous selection process, we are very pleased to have been chosen by Alligator. We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility (Sweden) enabled us to win this important program with Alligator in a highly competitive market place. We look forward to building a lasting relationship with Alligator Bioscience.”
Alligator will be taking advantage of Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello™ robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.
For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email firstname.lastname@example.org
For more information:
Last updated on: 12/06/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.